The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Thoas Fioretos

Thoas Fioretos

Research team manager

Thoas Fioretos

Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.

Author

  • Mats Jerkeman
  • P Aman
  • Eva Cavallin-Ståhl
  • E Torlakovic
  • Måns Åkerman
  • Felix Mitelman
  • Thoas Fioretos

Summary, in English

The purpose of this study was to investigate the prognostic implications of BCL6 rearrangement in a uniformly treated population of patients with diffuse large B-cell lymphoma (DLBCL) and to characterise the relationship between BCL6 rearrangement and prognostic factors. A total of 269 patients with DLBCL entered a randomised trial comparing the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) to the MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) regimen. In 44 cases, frozen tissue was available for assessment of BCL6 status by Southern blot analysis. BCL6 was rearranged in six of 43 evaluable cases (14%), and was associated with elevated lactate dehydrogenase (LDH), and a higher patient age. No association between BCL6 status and expression of BCL2, Ki-67 or TP53 was found. Patients presenting with BCL6 rearrangement displayed a weak trend towards better overall and failure-free survival (67 and 67% at 5 years), compared to patients with germline BCL6 (63 and 52%), but the difference was not statistically significant. In accordance with previously published series, the presence of BCL6 rearrangement does not define a prognostically distinct subgroup of DLBCL. Assessment of BCL6 status may, however, be of clinical interest when related to other prognostic variables.

Department/s

  • Breastcancer-genetics
  • Tumor microenvironment
  • Division of Clinical Genetics

Publishing year

2002

Language

English

Pages

161-165

Publication/Series

International Journal of Oncology

Volume

20

Issue

1

Document type

Journal article

Publisher

Spandidos Publications

Topic

  • Cancer and Oncology

Keywords

  • Gene Rearrangement B-Lymphocyte : genetics
  • Human
  • Immunophenotyping
  • Lymphoma B-Cell : drug therapy : genetics
  • Leucovorin : therapeutic use
  • Lactate Dehydrogenase : metabolism
  • Lymphoma Large-Cell Diffuse : drug therapy : genetics
  • Male
  • Methotrexate : therapeutic use
  • Middle Age
  • Neoplasm Staging
  • Prednisone : therapeutic use
  • Prognosis
  • Proto-Oncogene Proteins : genetics
  • Support Non-U.S. Gov't
  • Vincristine : therapeutic use
  • Transcription Factors : genetics
  • Doxorubicin : therapeutic use
  • DNA-Binding Proteins : genetics
  • DNA Neoplasm : analysis : metabolism
  • Cyclophosphamide : therapeutic use
  • Blotting Southern
  • Bleomycin : therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols : therapeutic use
  • Aged
  • Adolescence
  • Adult

Status

Published

ISBN/ISSN/Other

  • ISSN: 1019-6439